NDA 204819 · Bayer Hlthcare
Adempas
Riociguat · Oral · Soluble Guanylate Cyclase Stimulator
NovelOrphanLast checked: Nov 20, 2026Latest source record: Aug 4, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2013
Oct 8, 2013
Approved uses
2
Original approval plus efficacy supplements
Registered trials
57
11 Phase 3, 5 recruiting
FAERS reports
32,879
25,172 serious, 7,129 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: EMBRYO-FETAL TOXICITY Adempas is contraindicated for use during pregnancy because it may cause fetal harm based on animal data [see Contraindications (4.1) , Warnings and Precautions (5.1) , and Use in Specific Populations (8.1) ]. Exclude pregnancy prior to the start of treatment with Adempas. Advise use of effective contraception prior to initiation of treatment, during treatment, and for one month after treatment with Adempas [see Dosage and Administration (2.3) , Warnings and Precautions (5.1) , and Use in Specific Populations (8.3) ]. If pregnancy is detected, discontinue Adempas as soon as possible [see Warnings and Precautions (5.1) ]. WARNING: EMBRYO-FETAL TOXICITY See full prescribing information for complete boxed warning Based on animal data, Adempas may cause fetal harm if used during pregnancy. ( 4.1 , 5.1 , 8.1 ) Exclude pregnancy before start of treatment Use...
What it is approved for
From the label in effect Aug 13, 2026.
Adempas is a soluble guanylate cyclase (sGC) stimulator indicated for the treatment of adults with: • Persistent/recurrent Chronic Thromboembolic Pulmonary Hypertension (CTEPH) (WHO Group 4) after surgical treatment or inoperable CTEPH to improve exercise capacity and WHO functional class. ( 1.1 ) • Pulmonary Arterial Hypertension (PAH) (WHO Group 1) to improve exercise capacity, improve WHO functional class and to delay clinical worsening. ( 1.2 ) 1.1 Chronic-Thromboembolic Pulmonary Hypertension Adempas is indicated for the treatment of adults with persistent/recurrent chronic thromboembolic pulmonary hypertension (CTEPH), (WHO Group 4) after surgical treatment, or inoperable CTEPH, to improve exercise capacity and WHO functional class [see Clinical Studies (14.1) ]. 1.2 Pulmonary Arterial Hypertension Adempas is indicated for the treatment of adults with pulmonary arterial hypertension (PAH), (WHO Group 1), to improve exercise capacity, WHO functional class and to delay clinical worsening. Efficacy was shown in patients on Adempas monotherapy or in combination with endothelin receptor antagonists or prostanoids. Studies establishing effectiveness included predominately patients with WHO functional class II–III and etiologies of idiopathic or heritable PAH (61%) or PAH associated with connective tissue diseases (25%) [see Clinical Studies (14.2) ] .
Mechanism: Riociguat is a stimulator of soluble guanylate cyclase (sGC), an enzyme in the cardiopulmonary system and the receptor for nitric oxide (NO). When NO binds to sGC, the enzyme catalyzes synthesis of the signaling molecule cyclic guanosine monophosphate (cGMP). Intracellular cGMP plays an important role in regulating processes that influence vascular tone, proliferation, fibrosis and inflammation. Pulmonary hypertension is associated with endothelial dysfunction, impaired synthesis of nitric oxide and insufficient stimulation of the NO-sGC-cGMP pathway. Riociguat has a dual mode of action. It...
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Jan 11, 2018 Supplement 11 · Efficacy OrphanLetterLabel
- Oct 8, 2013 Original approval · Type 1 - New Molecular Entity NovelOrphanLabelSummary ReviewREMS
5 products under this application
- ADEMPAS · RIOCIGUAT 1MG · TABLET, ORAL · Prescription · TE AB
- ADEMPAS · RIOCIGUAT 2.5MG · TABLET, ORAL · Prescription · TE AB
- ADEMPAS · RIOCIGUAT 1.5MG · TABLET, ORAL · Prescription · TE AB
- ADEMPAS · RIOCIGUAT 0.5MG · TABLET, ORAL · Prescription · TE AB
- ADEMPAS · RIOCIGUAT 2MG · TABLET, ORAL · Prescription · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Riociguat" as an intervention, any sponsor and status, largest first.
- A Study to Evaluate Efficacy and Safety of Oral BAY63-2521 in Patients With Pulmonary Arterial Hypertension (PAH)Pivotal-lookingCompleted
BayerBayer (BAYRY)
NCT00810693 · 445 participants · Start Dec 17, 2008 · Primary completion May 14, 2012
Drug: Riociguat (Adempas, BAY63-2521); Riociguat (Adempas, BAY63-2521) and 1 more · For: Pulmonary Hypertension
Sites: Tucson, Arizona; La Jolla, California; Los Angeles, California · 122 sites in all
- BAY63-2521:Long-term Extension Study in Patients With Pulmonary Arterial HypertensionPivotal-lookingCompleted
BayerBayer (BAYRY)
NCT00863681 · 396 participants · Start Mar 12, 2009 · Primary completion Aug 19, 2019
Drug: Riociguat (BAY63-2521) · For: Hypertension, Pulmonary
Sites: Los Angeles, California; Sacramento, California; Aurora, Colorado · 99 sites in all
- A Study to Evaluate Efficacy and Safety of Oral BAY63-2521 in Patients With CTEPH.Pivotal-lookingCompleted
BayerBayer (BAYRY)
NCT00855465 · 262 participants · Start Feb 23, 2009 · Primary completion Jun 27, 2012
Drug: Riociguat (Adempas, BAY63-2521); Placebo · For: Pulmonary Hypertension
Sites: La Jolla, California; Sacramento, California; Miami, Florida · 89 sites in all
- BAY63-2521 - Long-term Extension Study in Patients With Chronic Thromboembolic Pulmonary HypertensionPivotal-lookingCompleted
BayerBayer (BAYRY)
NCT00910429 · 237 participants · Start Jul 1, 2009 · Primary completion Aug 19, 2019
Drug: Riociguat (Adempas, BAY63-2521) · For: Pulmonary Hypertension
Sites: La Jolla, California; Sacramento, California; Iowa City, Iowa · 73 sites in all
- Riociguat rEplacing PDE-5i Therapy evaLuated Against Continued PDE-5i thErapyPivotal-lookingCompleted
BayerBayer (BAYRY)
NCT02891850 · 225 participants · Start Jan 11, 2017 · Primary completion Jan 29, 2020
Drug: Riociguat (Adempas, BAY63-2521); Sildenafil and 1 more · For: Pulmonary Arterial Hypertension
Sites: Phoenix, Arizona; Tucson, Arizona; Sacramento, California · 81 sites in all
- A Study to Test the Effects of Riociguat in Patients With Pulmonary Hypertension Associated With Left Ventricular Systolic DysfunctionPivotal-lookingTerminated
BayerBayer (BAYRY)
NCT01065454 · 202 participants · Start Apr 14, 2010 · Primary completion Jun 6, 2012
Drug: Riociguat (Adempas, BAY63-2521); Riociguat (Adempas, BAY63-2521) and 2 more · For: Hypertension, Pulmonary; Ventricular Dysfunction, Left
Sites: Los Angeles, California; San Diego, California; Torrance, California · 83 sites in all
- Discontinuation Versus Continuation of Riociguat Monotherapy in Chronic Thromboembolic Pulmonary Hypertension Successfully Treated With Balloon Pulmonary AngioplastyPivotal-lookingNot yet recruiting
Assistance Publique - Hôpitaux de ParisAcademic, hospital or other
NCT07644377 · 150 participants (planned) · Start Nov 1, 2026 · Primary completion Jan 31, 2031
Drug: Discontinuation of riociguat · For: CTEPH
Sites: Angers, France; Bordeaux, France; Brest, France · 22 sites in all
- Efficacy and Safety of Riociguat in Patients With Symptomatic Pulmonary Hypertension (PH) Associated With Idiopathic Interstitial Pneumonias (IIP)Pivotal-lookingTerminated
BayerBayer (BAYRY)
NCT02138825 · 147 participants · Start Jun 4, 2014 · Primary completion May 5, 2016
Drug: Riociguat (Adempas, BAY63-2521); Placebo · For: Idiopathic Interstitial Pneumonias / Hypertension,Pulmonary
Sites: Los Angeles, California; San Francisco, California; Aurora, Colorado · 93 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- dyspnoea5,794
- death5,421
- headache4,575
- nausea3,819
- dizziness3,589
- diarrhoea3,574
- hypotension3,452
- fatigue3,021
- hospitalisation2,326
- vomiting2,147
- cough1,827
- oedema peripheral1,802
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2011 | 4 |
| 2012 | 10 |
| 2013 | 50 |
| 2014 | 837 |
| 2015 | 1,491 |
| 2016 | 2,606 |
| 2017 | 2,909 |
| 2018 | 3,297 |
| 2019 | 3,075 |
| 2020 | 3,101 |
| 2021 | 2,953 |
| 2022 | 2,850 |
| 2023 | 2,902 |
| 2024 | 3,038 |
| 2025 | 2,363 |
| 2026 | 1,393 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Adempas (Riociguat)
2024 spending
$694M
Beneficiaries
5,553
50,847 claims
Per beneficiary
$125,022
$154.23 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $463,152,406 |
| 2021 | $566,502,537 |
| 2022 | $576,981,088 |
| 2023 | $598,223,220 |
| 2024 | $694,246,753 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Update of EULAR recommendations for the treatment of systemic sclerosis.
Kowal-Bielecka O, Fransen J, Avouac J, et al. · Ann Rheum Dis 2017 · Consensus Statement, Practice Guideline
- Riociguat for the treatment of pulmonary arterial hypertension.
Ghofrani HA, Galiè N, Grimminger F, et al. · N Engl J Med 2013 · Clinical Trial, Phase III, Multicenter Study
- Treatment of pulmonary arterial hypertension in patients with connective tissue diseases: a systematic review and meta-analysis.
Erdogan M, Esatoglu SN, Kilickiran Avci B, et al. · Intern Emerg Med 2024 · Systematic Review, Meta-Analysis
- Riociguat for idiopathic interstitial pneumonia-associated pulmonary hypertension (RISE-IIP): a randomised, placebo-controlled phase 2b study.
Nathan SD, Behr J, Collard HR, et al. · Lancet Respir Med 2019 · Clinical Trial, Phase II, Multicenter Study
- Balloon pulmonary angioplasty versus riociguat for the treatment of inoperable chronic thromboembolic pulmonary hypertension (RACE): a multicentre, phase 3, open-label, randomised controlled trial and ancillary follow-up study.
Jaïs X, Brenot P, Bouvaist H, et al. · Lancet Respir Med 2022 · Clinical Trial, Phase III, Multicenter Study
- Switching to riociguat versus maintenance therapy with phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension (REPLACE): a multicentre, open-label, randomised controlled trial.
Hoeper MM, Al-Hiti H, Benza RL, et al. · Lancet Respir Med 2021 · Comparative Study, Multicenter Study
Sponsor: Bayer
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.